Salami Simpa S, Obedian Edward, Zimberg Shawn, Olsson Carl A
Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan.
Integrated Medical Professionals, Melville, New York.
Adv Radiat Oncol. 2016 Oct 29;1(4):310-316. doi: 10.1016/j.adro.2016.10.005. eCollection 2016 Oct-Dec.
Quality of life (QoL) outcomes play a major role in the treatment selection for prostate cancer (CaP). We evaluated the urinary QoL outcomes in men who were treated with image-guided intensity-modulated radiation therapy (IG-IMRT) for CaP.
We enrolled men who were diagnosed with CaP and underwent IG-IMRT in a large urological group practice into a prospectively maintained database. The typical radiation treatment dosage to prostates and seminal vesicles was 8100 cGy in 45 fractions. Urinary QoL was self-assessed using the standardized incontinence grade and International Prostate Symptom Score (IPSS) at baseline and at each follow-up visit. We evaluated the cumulative incidence of urinary incontinence and changes in both continence and IPSS over time.
Of the 3602 men who were eligible for analysis, 3086 (85.7%) had no urinary incontinence; 479 (13.3 %) had minimal incontinence (no requirement for pads), and 37 (1.0 %) had significant urinary incontinence that required the use of pads or interfered with activities of daily living, at baseline. After a median follow-up of 24 months (range: 12.0-41.0 months), these numbers were 80.6%, 17.4%, and 2.0%, respectively. Radiation therapy appeared to have a beneficial effect on some men: 54.1% of men with minimal incontinence became completely continent of urine during follow-up. Of those with significant urinary incontinence, 29.7% reported resolution and 27.0% reported improved symptoms with no requirement for pads. Of the 1276 men with moderate IPSS, the mean IPSS decreased from 12 to 9.8 at the time of the last follow-up ( < .001). Similarly, of the 233 men with severe IPSS, the mean IPSS decreased from 24 to 13 at the time of the last follow-up ( < .001).
IG-IMRT for clinically localized CaP is associated with a relatively low incidence of urinary incontinence. Although unexplained, IG-IMRT seems to improve symptoms in some men with baseline urinary incontinence and moderate-to-severe IPSS.
生活质量(QoL)结果在前列腺癌(CaP)治疗方案的选择中起着重要作用。我们评估了接受图像引导调强放射治疗(IG-IMRT)的CaP男性患者的泌尿生活质量结果。
我们将在一个大型泌尿外科团体诊所被诊断为CaP并接受IG-IMRT的男性患者纳入一个前瞻性维护的数据库。前列腺和精囊的典型放射治疗剂量为45次分割共8100 cGy。在基线和每次随访时,使用标准化尿失禁分级和国际前列腺症状评分(IPSS)对泌尿生活质量进行自我评估。我们评估了尿失禁的累积发生率以及随时间推移尿失禁和IPSS的变化。
在3602名符合分析条件的男性中,3086名(85.7%)无尿失禁;479名(13.3%)有轻度尿失禁(无需使用尿垫),37名(1.0%)有严重尿失禁,需要使用尿垫或影响日常生活活动,这是基线时的情况。中位随访24个月(范围:12.0 - 41.0个月)后,这些数字分别为80.6%、17.4%和2.0%。放射治疗似乎对一些男性有有益影响:54.1%的轻度尿失禁男性在随访期间完全不再尿失禁。在那些有严重尿失禁的男性中,29.7%报告症状消失,27.0%报告症状改善且无需使用尿垫。在1276名IPSS为中度的男性中,最后一次随访时IPSS的平均值从12降至9.8(P <.001)。同样,在233名IPSS为重度的男性中,最后一次随访时IPSS的平均值从24降至13(P <.001)。
临床局限性CaP的IG-IMRT与相对较低的尿失禁发生率相关。尽管原因不明,但IG-IMRT似乎能改善一些基线时有尿失禁且IPSS为中度至重度的男性的症状。